BPC-157 & KPV Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

BPC-157 & KPV Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic 15-amino-acid gastric pentadecapeptide studied in animal models for tissue repair, angiogenesis, and GI protection.

BPC-157 has been shown in rodent and cell-culture studies to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) and activate downstream Akt–eNOS signaling, promoting endothelial nitric oxide production and new vessel formation. The peptide also engages the focal adhesion kinase (FAK)–paxillin pathway, facilitating endothelial cell migration during angiogenesis. Additional preclinical data indicate modulation of nitric oxide synthesis more broadly, with context-dependent protective effects against cytotoxic NO excess while preserving physiological NO-mediated functions. These converging angiogenic and cytoprotective pathways are proposed to underlie observations of accelerated wound closure, tendon reattachment, and gastrointestinal mucosal recovery in animal injury models.

Molar mass

1419.5 g/mol

C-terminal tripeptide of α-MSH (Lys-Pro-Val) that suppresses NF-κB-driven inflammation and is absorbed by intestinal PepT1 transporters in preclinical models.

KPV inhibits the NF-κB signaling pathway, blocking nuclear translocation of the p65 subunit and reducing downstream transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Unlike the full α-MSH molecule, KPV's anti-inflammatory activity appears to be partially independent of classical melanocortin receptor engagement, suggesting intracellular or alternative receptor mechanisms that remain under investigation. In intestinal epithelia, KPV is actively transported into cells via the proton-coupled oligopeptide transporter PepT1 (SLC15A1), which is upregulated in inflamed colonic mucosa, potentially creating preferential delivery to inflamed sites. Additional activity in keratinocytes and macrophages involves suppression of MAP-kinase signaling cascades alongside NF-κB, consistent with broad attenuation of innate immune activation.

Molar mass

192.21 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Vasireddi et al. 2025 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS J; PMID 40756949; PMC12313605) — COMPONENT-LEVEL (BPC-157), NOT blend-level. 544 screened 1993–2024; 36 included = 35 preclinical + 1 uncontrolled human. Does not mention KPV or a combined product.
• Dalmasso et al. 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology 134(1):166-78; PMID 18061177) — COMPONENT-LEVEL (KPV), NOT blend-level. Oral KPV reduced DSS/TNBS colitis in mice via PepT1 uptake and NF-κB/MAP-kinase inhibition; no BPC-157 co-administration.
• Getting, Schiöth & Perretti 2003 — Dissection of the anti-inflammatory effect of core and C-terminal (KPV) alpha-MSH peptides (J Pharmacol Exp Ther 306(2):631-7; PMID 12750433) — COMPONENT-LEVEL (KPV), NOT blend-level. KPV's anti-inflammatory action is melanocortin-receptor-independent, attributed to IL-1β-function inhibition.
• Singh & Mukhopadhyay 2014 — Alpha-MSH: An Emerging Anti-Inflammatory Antimicrobial Peptide (BioMed Research International) — COMPONENT-LEVEL (KPV / alpha-MSH), NOT blend-level. Identifies KPV as the minimal C-terminal alpha-MSH fragment retaining anti-inflammatory/antimicrobial activity.
• Sung et al. 2025 — KPV mitigates fine-dust-induced keratinocyte apoptosis/inflammation via oxidative-stress/MAPK/NF-κB modulation (Tissue Cell 95:102837; PMID 40073467) — COMPONENT-LEVEL (KPV), NOT blend-level. In-vitro human keratinocyte (HaCaT) model — not a human-outcome or blend study.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: No formal PK exists for the blend as a unit; every pharmacokinetic value below is component-level (BPC-157 or KPV alone). Commercially, this exact 2-component product is sold predominantly ORAL — a manufactured liposomal oral liquid (Quicksilver Scientific) plus several oral-capsule products, per the commerce section, which found NO classic reconstituted-vial RUO market for the pure pairing. Subcutaneous (SC) is the packaging convention for adjacent multi-peptide research blends, not the dominant format for this specific blend.

No PK study of the BPC-157 + KPV blend as a unit administered SC. Component-level only: neither BPC-157 nor KPV has a published SC pharmacokinetic study in any species. SC is a marketed format for the components and for adjacent multi-peptide research blends, but for THIS specific 2-component product the commerce section found oral formats (liposomal liquid + capsules) to be the dominant real retail footprint — so SC here reflects a commercial/community pattern for the peptide class, not a studied route or the dominant format for this exact blend.

Bioavailability: No published SC bioavailability, Cmax, or half-life data for either component alone or as a combined blend. Comprehensive BPC-157 PK/route reviews report no SC-specific value.

A packaging/community format, not a studied route; no controlled study has characterized SC pharmacokinetics of either peptide, individually or combined. No human dosing implied.

Component-level, not blend-level: BPC-157 was formally characterized in the single published PK study (Sprague-Dawley rats + beagle dogs, incl. repeated 7-day IM dosing). No IM study for KPV, and none for the blend.

Bioavailability: BPC-157 absolute IM bioavailability ≈14–19% in rats and ≈45–51% in dogs; rat Tmax ~3 min; elimination half-life <30 min — component data only, preclinical, species-dependent. No comparable KPV or blend data.

One of only two routes with any published pharmacokinetics among this blend's components — and that PK belongs to BPC-157 alone, in animals, not to KPV or the combined blend.

Component-level, not blend-level: BPC-157 was characterized in the same rat/dog PK study, with IV as the reference route for elimination half-life. No IV study for KPV or the blend.

Bioavailability: 100% bioavailable by definition; BPC-157 elimination half-life ~15.2 min (rat) and ~5.27 min (dog), rapidly metabolized to fragments/amino acids — component data only. No equivalent KPV or blend IV finding.

Defines BPC-157's short plasma half-life; reviews note its biological effects appear to outlast the brief plasma presence. Preclinical, and component-level, not a blend or human finding.

Component-level, not blend-level: BPC-157 is a heavily used systemic dosing route in the rat/mouse efficacy literature. Published KPV colitis studies use oral or intracolonic dosing, not IP; no IP KPV study was found this pass.

Bioavailability: No dedicated IP pharmacokinetic characterization for BPC-157 — used as an efficacy-study dosing route, not a PK route. No KPV or blend IP data.

A laboratory-animal administration route documented for the BPC-157 component only, cited to describe how preclinical efficacy work was conducted — not a blend finding and not a human route.

Component-level, not blend-level — but both components have independent oral preclinical evidence: BPC-157 is stable in human/simulated gastric juice >24 h and studied via drinking-water/intragastric dosing in rodent GI models; KPV is PepT1-transported and reduced colitis when given orally in murine DSS/TNBS models (Dalmasso et al. 2008). No study has tested the two peptides together by any oral route.

Bioavailability: BPC-157's gastric-fluid survival is not demonstrated systemic oral bioavailability (never quantified in any species). KPV's oral effect is PepT1-dependent, concentrated at inflamed gut tissue (PepT1 upregulated in colitis) — a gut-tissue-targeted local action, abolished in PepT1-knockout mice, confirming transporter-dependence rather than passive systemic absorption.

The best-evidenced route for either individual component (both preclinical, animal-model), but no study has examined BPC-157 and KPV administered together orally. Local GI-tract mechanisms in rodents, not systemic human oral bioavailability, and never a human protocol.

Component-level, not blend-level, and minimally studied for either component: BPC-157 intranasal use is limited to informal community/vendor nasal-spray products with no published animal or human study; no published study of intranasal KPV delivery was found — nasal KPV products extrapolate from general peptide nasal-delivery, not KPV-specific data.

Bioavailability: No intranasal PK or bioavailability data exist for BPC-157, KPV, or the blend. Any 'nose-to-brain'/enhanced-systemic-uptake rationale is extrapolated from other molecules and not demonstrated for either component.

A vendor-marketed format (nasal spray) sold for both components individually and in some blends; not a literature-derived or blend-tested route.

Component-level, not blend-level: BPC-157 studied topically in animal wound/burn models (local healing markers); KPV studied ex vivo on microporated human skin for transdermal iontophoretic delivery. No topical study of the combined blend.

Bioavailability: BPC-157: systemic skin absorption was not quantified in the cited animal wound work (describes local action). KPV: passive transdermal permeation was below the assay's detection limit (<0.01 µg/mL) in ex vivo human skin — measurable flux required active enhancement (iontophoresis ~8×; iontophoresis + microneedle pretreatment ~35× vs microneedle alone), i.e. any KPV topical delivery depends on an active technique, not simple application.

Both components have topical/local evidence only at the component level, in animal or ex vivo human-skin models — never as the combined blend, and never demonstrating unassisted passive human topical absorption.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 — · median $3.50 · p75 — · 11 researched vendors

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$35

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

No independent-lab aggregate purity report specific to a combined 'BPC-157 & KPV Blend' (two-component) product was found — the pure-pairing market appears thin; vendors instead bundle BPC-157 and KPV with TB-500 and/or GHK-Cu (e.g. the 4-peptide KLOW blend). Component-level, not blend-level: Finnrick's BPC-157 vendor aggregate (666 samples / 98 vendors) clusters ~96.8–99.95% HPLC purity; Janoshik-verified single-vendor KPV batches report 99.216% (Chameleon Peptides, lot B001) and 99.22% HPLC (Panda Peptides, lot PP2601, task ID 113197).

Independent labs cited for this compound

No FDA recall or market withdrawal was found specifically targeting a 'BPC-157 & KPV Blend' product (or either component individually). As unapproved/RUO-labeled research chemicals sold outside the regulated supply chain, FDA/DOJ action takes the form of warning letters, import detention, and criminal prosecution rather than Class I/II/III recalls (see events). Reported honestly as an empty recall result — none found — not invented.

Buyer red-flag checklist

• No FDA-approved drug application exists for BPC-157, KPV, or any product marketed as 'BPC-157 & KPV Blend'.
• Both components were placed in interim 503A Category 2 in Sept 2023; their nominations were later withdrawn and they are now scheduled for the July 23-24, 2026 PCAC review for possible 503A Bulks List inclusion — none of this is FDA approval or authorization to compound.
• An RUO label is not an importation exemption: unapproved new drugs like these can face FDA border detention (Import Alert 66-41 authorizes DWPE of unapproved new drugs generally, though it does not name these peptides by name).
• No published randomized controlled trial exists for a BPC-157+KPV combined product; evidence is limited to each component's separate preclinical/clinical literature (see evidence section).
• The market for a pure two-component BPC-157+KPV product is thin — most vendor 'blends' bundle in TB-500 and/or GHK-Cu, so confirm the exact peptide list on any product before assuming it matches this two-component pairing.
• Short peptides like KPV are commonly sold as TFA/acetate salts; a COA or label reporting only total vial mass (not free-base-equivalent peptide mass) can overstate actual active content.
• No batch-specific COA provided on request is a widely-cited community/industry rule-of-thumb for assuming underdosed or substituted product.
• A COA report/task ID that does not resolve in the testing lab's own public verification database is treated industry-wide as a fabricated or edited certificate.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent-lab aggregate quantifying underdosing/mislabeling prevalence for a combined BPC-157+KPV blend was found. Component-level, not blend-level: Finnrick's BPC-157 aggregate reports advertised-mg-vs-label divergence of up to ±71% at the 95th percentile, and an independent 10-sample MZ Biolabs investigation (Jan 2026) failed 3 of 10 tested peptides on purity/identity — KPV was not among that sample set. Separately, buying-guide sources note that short peptides such as KPV are often supplied as TFA/acetate salts, where labeled vial mass can include non-active counter-ion weight — a generic labeling-math risk (not unique to this blend, not independently lab-quantified here) that can overstate active content when free-base-equivalent mass isn't disclosed.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.', last revised 05/19/2026) authorizes DWPE via a firm-specific Red List. It does NOT name BPC-157, KPV, or a BPC-157/KPV blend as listed substances. Because neither peptide has an FDA-approved drug application, a research-peptide shipment could in principle be detained under 66-41's general unapproved-new-drug authority if the importing firm is red-listed — but no primary source establishes 66-41 targeting BPC-157/KPV by name, and an RUO label is not itself an importation exemption (FDA/CBP judge actual marketed/intended use).66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

The BPC-157 & KPV blend itself is not named on the WADA Prohibited List (no product-level schedule exists for a named blend). Per component: BPC-157 is prohibited at all times, in- and out-of-competition, under S0 (Non-Approved Substances) — confirmed by an explicit USADA advisory; with no approved human therapeutic use, a Therapeutic Use Exemption would not be granted. KPV could NOT be confirmed as specifically named on any official WADA/USADA page checked this pass; it is prohibited only by the general S0 catch-all inference (any pharmacological substance without government therapeutic approval and not addressed elsewhere), reported here as an inference, not a confirmed named listing. Neither component is a GHRP/GHRH, so WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) does not apply to either — an 'S2' tag for either would be a vendor-blog mischaracterization.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Direct aggregate discourse naming a two-peptide 'BPC-157 & KPV Blend' product specifically (vs the individual compounds or the four-peptide KLOW blend) could not be confirmed via primary linkable threads (no Reddit/YouTube/Bluesky/X thread located); themes/concerns are inferred from secondary aggregator/blog write-ups, not primary threads — treat as illustrative.
• Multiple secondary sources conflate this two-peptide blend with the four-peptide KLOW blend, likely inflating apparent discussion volume; the conflation is reported here only as a discussion theme, not as evidence of dedicated two-peptide-blend discourse.
• Sample is illustrative and thin, reflecting the blend's narrow commercial footprint (per the commerce section: a licensed-practitioner liposomal product plus a few capsule SKUs, no pure-pairing RUO vial) versus its far more widely sold four-peptide KLOW counterpart.
• The oral-dosing-equivalence point (reportedConcerns[0]) draws on KPV's own preclinical oral-bioavailability profile — a COMPONENT-LEVEL fact, not a blend-level measurement; no oral-bioavailability study of the 2-peptide blend as a unit exists.
• Secondary aggregator/vendor-blog sources (PeptideDeck, mypeptidematch, Juve Integrative, AgeRejuvenation, Peptidepedia, and clinic blogs) have a commercial interest in favorable framing of peptide stacks; treat the positive-mix share as an upper-bound estimate.

Manually researched from reddit— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet